Summary
mAb 174H.64, which selectively recognizes an epitope expressed on the proliferating cells of mammalian squamous carcinomas, was covalently coupled to daunomycin (DM) by an acid-sensitive linker and tested for its selective cytotoxicity for squamous carcinomas. A murine lung squamous carcinoma model for chemoimmunotherapy using mAb 174H.64-DM conjugates was developed. This model utilizes the KLN-205 cell line, which metastasizes to the lungs following i.v. injection and shows a pattern of growth similar to those of spontaneous squamous carcinomas, characterized by highly proliferative cells at the periphery of the tumor (reactive with 174H.64) with the keratinized differentiated cells toward the center (not reactive with 174H.64). 174H.64-DM conjugates showed marked and specific cytotoxicity against KLN-205 cells both in vitro and following i.v. injection of the immunoconjugate in mice with established lung metastases. The conjugate was nearly as effective as daunomycin alone when incubated in vitro with KLN-205 cells and much more effective than daunomycin alone in vivo or other control immunoconjugates, which were ineffective. Finally, while the free 174H.64 mAb produced a significantly increased time of survival of mice bearing KLN-205 metastases, a much greater survival was found with mice treated with the 174H.64-DM immunoconjugate, some mice apparently demonstrating long-term survival (>100 days). We conclude that mAb 174H.64 may have potential therapeutic benefit against squamous carcinoma.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsuruo T, Pinedo HM, Lankelma J (1988) Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with p-glycoprotein. Biochem Pharmacol 37: 2389
Diaz LA, Sampaio SAP, Martins CR, Rivitti EA, Macca ML, Roscoe JT, Takahashi Y, Labib RS, Patel HP, Mutasim DF, Dugan EM, Anhalt GJ (1987) An autoantibody in pemphigus serum, specific for the 59 kD keratin, selectively binds the surface of keratinocytes: evidence for an extracellular keratin domain. J Invest Dermatol 89: 287
Diener E, Diner UE, Sinha A, Vergidis R (1986) Specific immunosuppression by immunotoxins containing daunomycin. Science 231: 148
Diener E, Yu L, Samuel J, Longenecker BM, Xie S, Du S-Y (1988) The use of cytotoxic drug-immunoconjugates in experimental models of immunotherapy. In: Cellular basis of immune modulation. Alan R. Liss, New York, p 509
Diener E, Xie S, Yu L, Longenecker BM, Sinha A (1988) Experimental application of target-specific immunoconjugate containing daunomycin as the cytocidal component. In: Antibody-mediated delivery systems. Marcel Dekker, New York, p 1
Dillman RO (1984) Monoclonal antibodies in the treatment of cancer. CRC Crit Rev Oncol Hematol 1: 357
Dillman RO, Johnson DE, Shawler DL, Koziol JA (1988) Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48: 6097
Ding L, Yu L, Xie S, Gong D, Vergidis R, Diener E (1990) The application of target-specific drug-immunoconjugates to experimental bone marrow replacemental therapy. Cancer Res 50: 1528
Ferenczy A (1982) Carcinoma and other malignant tumors of the cervix: In: Pathology of the female genital tract. Springer, Berlin Heidelberg New York, p 184
Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzger R, Aulakh G, Ting R, Ruscetti F, Gallo R (1979) Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54: 713
Gallego J, Price MR, Baldwin RW (1984) Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity. Int J Cancer 33: 737
Janowska-Wieczorek A, Mannoni PJ, Krantz MJ, Turner AR and Turc JM (1986) Inhibition of CFU-GM, BFU-E and CFU-GEMM colony formation by monoclonal antibodies selected from the myeloid panel. In: Leukocyte typing II, vol 3. Human myeloid and hematopoietic cells, Springer, Berlin Heidelberg New York, p 171
Kaneko T, LePage GA (1978) Growth characteristics and drug responses to a murine lung carcinoma in vitro and in vivo. Cancer Res 38: 2084
Pimm MV, Paul MA, Ogumuyiwa Y, Baldwin RW (1988) Biodistribution and tumor localization of a daunomycin-monoclonal antibody conjugate in nude mice human tumor xenografts. Cancer Immunol Immunother 27: 267
Samuel J, Noujaim AA, Willans DJ, Brzezinska GS, Haines DM, Longenecker BM (1989) A novel marker for basal (stem) cells of mammalian stratified squamous epithelia and squamous cell carcinomas. Cancer Res 49: 2465
Shen WC, Ryser HJP (1981) Cis-aconityl spacer between daunomycin and macro molecular carrier: a model of pH-sensitive linkage releasing drug from a liposomotropic conjugate. Biochem Biophy Res Commun 102: 1048
Williams ML, Nettesheim P (1973) Lung colony assay with a squamous cell carcinoma derived from the respiratory tract of mice. J Natl Cancer Inst 51: 1513
Wolosin LB, Greenberg AH (1979) Murine natural anti-tumor antibodies. I. Rapid in vivo finding of natural antibody by tumor cells in syngeneic mice. Int J Cancer 23: 519
Xie S, Inazawa M, Sinha A, Sawada S, Vergidis R, Diener E (1987) Facilitation of allogeneic bone marrow transplantation by a T cell-specific immunotoxin containing daunomycin. Transplantation 44: 770
Zimmerman J, Vidrich A, Gilmartin M, Freedberg IM (1982) An extra-cellular subset of ME 180 keratins. J Cell Biol 95: 237a
Author information
Authors and Affiliations
Additional information
This work was supported by the Medical Research Council of Canada and Biomira Inc.
Rights and permissions
About this article
Cite this article
Ding, L., Samuel, J., MacLean, G.D. et al. Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas. Cancer Immunol Immunother 32, 105–109 (1990). https://doi.org/10.1007/BF01754206
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01754206